Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Criteria Bio Ventures is a Life Sciences venture fund founded to support private biotech companies primarily in Europe and North America, with a focus on Spain and Portugal. The firm has a portfolio of six companies and aims to partner with entrepreneurs to advance healthcare innovations addressing significant unmet medical needs.
This firm invests across various therapeutic modalities and disease areas, providing evergreen support to companies until they achieve meaningful impact. Criteria Bio Ventures is committed to backing disruptive and well-protected innovations in the Life Sciences sector.
Notable portfolio companies include Aboleris Pharma, which develops immunotherapy for autoimmune diseases; Sanifit, acquired by Vifor Pharma for its work on calcification disorders; Northern Biologics, whose assets were acquired by Boehringer Ingelheim and AstraZeneca; Minoryx Therapeutics, co-led in its Series C funding round; Adaptam Therapeutics, focusing on myeloid immunosuppression in cancer; and Aelix, which is developing a new therapeutic HIV vaccine.
Email info@criteriabioventures.com with your deck to pitch them.
Yes, Criteria Bio Ventures actively participates in funding rounds and has co-led Series C funding for companies like Minoryx Therapeutics.
The firm provides evergreen support, indicating a willingness to participate in follow-on investments as companies progress.
Specific fund size details are not disclosed, but the firm maintains a portfolio of six notable companies.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.